One of the few bright spots in Boston’s life-science lab space market this year has dimmed.

Analysis of Ginkgo Bioworks' Q3 results and business model, with a focus on growth, customer acquisition and cash flow ...

In a report released yesterday, Tejas Savant from Morgan Stanley maintained a Hold rating on Ginkgo Bioworks Holdings (DNA – Research Report), ...

Ginkgo Bioworks reported mixed Q3, with a $45M one-time revenue boost masking underlying revenue growth issues. Read why I ...

Q3 2024 Earnings Call Transcript November 12, 2024 Megan LeDuc: Good evening. I’m Megan LeDuc, Manager of Investor Relations ...

Third Quarter 2024 Results Key Financial Results Revenue: US$89.0m (up 61% ...

Ginkgo Bioworks is offering its newly-completed Boston Seaport lab complex for sublease as it shrinks its real estate ...

Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the ...

BTIG analyst Mark Massaro lowered the firm’s price target on Ginkgo Bioworks (DNA) to $6 from $7 and keeps a Sell rating on the shares ...

Return on Assets (ROA): Ginkgo Bioworks Holdings's ROA lags behind industry averages, suggesting challenges in maximizing ...

Ginkgo Bioworks (DNA) delivered earnings and revenue surprises of 55% and 102.77%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

BOSTON, Nov. 12, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the completion of the first ...